Clinical Trial

Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

Study acronym: ALTER-UC-011
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomy
Trial Details
NCT Number NCT07627464
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Renal Cell Carcinoma (RCC)
Enrollment 144 participants
Start Date 2026-05-31
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-04